Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94.
The average 50% inhibitory concentration (IC(50)) values for AD169 were 0.22 +/- 0.09 microM 1263W94 and 5.36 +/- 0.12 microM ganciclovir. For 35 human cytomegalovirus (HCMV) clinical isolates the average IC(50) was 0.42 +/- 0.09 microM 1263W94, and for 26 ganciclovir-susceptible HCMV clinical isolates the average IC(50) was 3.78 +/- 1.62 microM ganciclovir. Nine HCMV clinical isolates that were resistant to ganciclovir were completely susceptible to 1263W94.
McSharry
J J
JJ
Center for Immunology and Microbial Disease, Albany Medical College, Albany, New York 12208, USA. mcsharj@mail.amc.edu
McDonough
A
A
Olson
B
B
Talarico
C
C
Davis
M
M
Biron
K K
KK
D019380:Anti-HIV Agents / Q000494:pharmacology*; D000998:Antiviral Agents / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D003587:Cytomegalovirus / Q000187:drug effects* / Q000235:genetics; D004279:DNA, Viral / Q000032:analysis; D005347:Fibroblasts / Q000821:virology; D005434:Flow Cytometry; D015774:Ganciclovir / Q000494:pharmacology*; D006801:Humans; D020128:Inhibitory Concentration 50; D009693:Nucleic Acid Hybridization; D012263:Ribonucleosides / Q000494:pharmacology*; D010948:Viral Plaque Assay; D004004:Dichlororibofuranosylbenzimidazole / Q000031:analogs & derivatives
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D001562:Benzimidazoles; D004279:DNA, Viral; D015774:Ganciclovir; D012263:Ribonucleosides; C400401:maribavir; D004004:Dichlororibofuranosylbenzimidazole